Aytu biopharma appoints dr. gerwin westfield as senior vice president of scientific affairs to support commercialization of exxua(tm)

Denver, co / access newswire / june 25, 2025 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced the appointment of dr. gerwin westfield, phd as senior vice president of scientific affairs, effective june 30, 2025. in his role, dr. westfield will oversee the company's medical and scientific affairs strategies, with a primary focus on the upcoming commercial launch of exxua™ (gepirone) extended-release tablets ("exxua"), a novel, branded, united states food and drug administration ("fda") approved treatment for major depressive disorder ("mdd") in adults in the united states.
AYTU Ratings Summary
AYTU Quant Ranking